These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 6529497)
1. [Stability of parenteral formulations of apomorphine]. Pandolfo V; Tanini R; Polidori G; Santoni G Boll Chim Farm; 1984 Sep; 123(9):449-52. PubMed ID: 6529497 [No Abstract] [Full Text] [Related]
2. Labile iron in parenteral iron formulations: a quantitative and comparative study. Coyne DW Nephrol Dial Transplant; 2004 Oct; 19(10):2674-5; author reply 2675-6. PubMed ID: 15388831 [No Abstract] [Full Text] [Related]
3. Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management. Antonini A; Tolosa E Expert Rev Neurother; 2009 Jun; 9(6):859-67. PubMed ID: 19496689 [TBL] [Abstract][Full Text] [Related]
4. Stability of parenteral midazolam in an oral formulation. Walker SE; Grad HA; Haas DA; Mayer A Anesth Prog; 1997; 44(1):17-22. PubMed ID: 9481976 [TBL] [Abstract][Full Text] [Related]
6. Preformulation stability testing of parenteral products. Zoglio MA Bull Parenter Drug Assoc; 1968; 22(6):295-8. PubMed ID: 5727165 [No Abstract] [Full Text] [Related]
7. Apomorphine in dopaminergic therapy. Subramony JA Mol Pharm; 2006; 3(4):380-5. PubMed ID: 16889431 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of apomorphine in Parkinson's disease. Gancher S J Neural Transm Suppl; 1995; 45():137-41. PubMed ID: 8748619 [TBL] [Abstract][Full Text] [Related]
9. Preliminary study on the potential utility of GFP as a biosensor for drug stability in parenteral solutions. dos Santos CA; Mazzola PG; Silva PH; Cholewa O; Penna TC Biotechnol Prog; 2007; 23(4):979-84. PubMed ID: 17567040 [TBL] [Abstract][Full Text] [Related]
10. [Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations]. Castaño B; Mateo D; Giménez-Roldán S Neurologia; 2007 Apr; 22(3):133-7. PubMed ID: 17364250 [TBL] [Abstract][Full Text] [Related]
11. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Manson AJ; Turner K; Lees AJ Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062 [TBL] [Abstract][Full Text] [Related]
12. Implementation and automation of a particle detection system for parenteral products. Knapp JZ; Kushner HK J Parenter Drug Assoc; 1980; 34(5):369-93. PubMed ID: 6905868 [No Abstract] [Full Text] [Related]
13. Stabilizers for parenteral drugs. Scheindlin S Bull Parenter Drug Assoc; 1966; 20(2):61-4. PubMed ID: 5905230 [No Abstract] [Full Text] [Related]
14. Stability of apomorphine in frozen plasma samples. Smith RV; Humphrey DW; Wilcox RE Res Commun Chem Pathol Pharmacol; 1980 Jan; 27(1):183-6. PubMed ID: 7360998 [TBL] [Abstract][Full Text] [Related]